Insulin glargine and lixisenatide Subcutaneous and Neo-Synalar Cream
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Neo-Synalar Cream and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: fluocinolone / neomycin topical
Brand name: Neo-Synalar
Synonyms: Neo-Synalar
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Neo-Synephrine (Phenylephrine (Nasal))
- Insulin glargine and lixisenatide Subcutaneous-Neo-Synephrine (Phenylephrine Injection)
- Insulin glargine and lixisenatide Subcutaneous-Neo-Synephrine 12 Hour
- Insulin glargine and lixisenatide Subcutaneous-Neo-Synephrine 12 Hour Spray
- Insulin glargine and lixisenatide Subcutaneous-Neo-Synephrine Cold & Sinus
- Insulin glargine and lixisenatide Subcutaneous-Neo-Synephrine Injection
- Neo-Synalar Cream-Insulin glargine, recombinant Subcutaneous
- Neo-Synalar Cream-Insulin glulisine
- Neo-Synalar Cream-Insulin Glulisine (Cartridges and Pens)
- Neo-Synalar Cream-Insulin Glulisine (Vials)
- Neo-Synalar Cream-Insulin glulisine Subcutaneous
- Neo-Synalar Cream-Insulin human inhaled Inhalation